Weight-loss drugs are becoming a popular employee perk, with almost a third of workers saying they’d switch jobs to get GLP-1 coverage. Now, Bank of America is spending $250 million or more yearly on the drugs for its staffers—and CEO Brian Moynihan says the upsides are well-worth the eye-watering cost.
“What we see is a great impact on the employees,” Moynihan recently said in an interview with CNBC. “We’ve always been about mental wellness, physical wellness.”
